Williams M H, Kreider R B, Hunter D W, Somma C T, Shall L M, Woodhouse M L, Rokitski L
Department of Health, Physical Education and Recreation, College of Education, Old Dominion University, Norfolk, VA 23529-0196.
Med Sci Sports Exerc. 1990 Aug;22(4):517-22.
The purpose of this study was to investigate the ergogenic effect of oral inosine (IN) supplementation (6,000 mg.d-1 for 2 d) upon 3-mile run time (3MTIME) and VO2 peak. Nine highly trained endurance runners participated in a double-blind, placebo (PL), crossover study. Each subject undertook an IN or PL trial, consisting of three exercise tests: a submaximal warm-up run (SUBRUN), a competitive 3-mile treadmill run (3MRUN), and a maximal treadmill run (MAXRUN) to determine VO2 peak and time to exhaustion (MAXTIME). Additional measurements during the 3MRUN and MAXRUN included oxygen uptake (VO2), ventilation (VE), respiratory exchange ratio (R), and ratings of perceived exertion (RPE); blood samples were also taken prior (PRERUN) to the SUBRUN test and following the SUBRUN, 3MRUN, and MAXRUN tests in order to assess glucose, pyruvate, lactate, phosphorus, 2,3-DPG, hemoglobin, and uric acid. Analyses of the data revealed no significant effect of oral IN supplementation either upon 3MTIME (IN = 18.31 +/- 1.21; PL = 18.33 +/- 1.15 min) or VO2 peak (IN = 58.6 +/- 5.1; PL = 60.7 +/- 4.5 ml O2.kg-1.min-1) or upon other dependent variables. MAXTIME was significantly longer during the PL trial (P less than 0.05), suggestive of a possible impairment effect of oral IN supplementation. Based upon our data, we conclude that IN is not an effective ergogenic aid to enhance athletic performance of an aerobic nature.
本研究的目的是调查口服肌苷（IN）补充剂（6000毫克/天，持续2天）对3英里跑时间（3MTIME）和最大摄氧量（VO2峰值）的促力效果。九名训练有素的耐力跑运动员参与了一项双盲、安慰剂（PL）交叉研究。每位受试者进行一次IN或PL试验，包括三项运动测试：次最大强度热身跑（SUBRUN）、3英里竞争性跑步机跑步（3MRUN）和最大强度跑步机跑步（MAXRUN），以确定VO2峰值和疲劳时间（MAXTIME）。在3MRUN和MAXRUN期间的其他测量包括摄氧量（VO2）、通气量（VE）、呼吸交换率（R）和主观用力程度评级（RPE）；在SUBRUN测试前（PRERUN）以及SUBRUN、3MRUN和MAXRUN测试后采集血样，以评估葡萄糖、丙酮酸、乳酸、磷、2,3 - 二磷酸甘油酸、血红蛋白和尿酸。数据分析显示，口服IN补充剂对3MTIME（IN = 18.31 +/- 1.21；PL = 18.33 +/- 1.15分钟）或VO2峰值（IN = 58.6 +/- 5.1；PL = 60.7 +/- 4.5毫升氧气·千克-1·分钟-1）或其他因变量均无显著影响。在PL试验期间MAXTIME显著更长（P小于0.05），提示口服IN补充剂可能有损害作用。基于我们的数据，我们得出结论，IN不是增强有氧运动表现的有效促力辅助剂。
